China Biologic amends Congqing Dalin deal

Taian City-based China Biologic Products, one of the leading plasma-based pharmaceutical companies in China, announced that, on  December 12, the company further amended its agreement relating to the  acquisition of a 90% controlling interest in Chongqing Dalin Biologic  Technologies. Dalin owns 54% of the equity interests in Qianfeng  Biological Products, one of the largest plasma-based biopharmaceutical  companies in China, located in Guiyang, Guizhou Province.

The acquisition will transform the company into the biggest  non-state-owned producer of plasma-based biopharmaceutical products in  China, in terms of market share and production capacity. Qianfeng is one  of the largest plasma-based biopharmaceutical companies in China and the  only operating manufacturer in Guizhou Province, which has a population  of 39 million. It produces about 250 tons of products a year with annual  production capacity of 400 tons. Qianfeng also owns seven plasma  collection stations in Guizhou, of which six are currently in operation.  Will lift market share to 15.6%

China Biologic believes that Qianfeng currently has an around 9.5%  market share in China, compared to its own 6.1%, which would result in a  combined market share of some 15.6%. The top six largest plasma-based  biopharmaceutical companies in China, including Qianfeng, have a total  market share of about 50%.